Article History
Received: 30 August 2021
First Online: 23 September 2021
Declarations
:
: WO has received lecture fees from Dainippon-Sumitomo Pharma, Novartis, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Abbott Japan as well as research funding from Noster, Nippon Boehringer Ingelheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Nippon Eli-Lilly, Novo Nordisk Pharma, Abbott Japan, Abbott Diabetes Care UK Ltd, Dainippon-Sumitomo Pharma. WO has received subsidies or donations from Kowa Pharmaceutical, Novo Nordisk Pharma, Astellas, Dainippon-Sumitomo Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, Abbott Japan, Novartis, Daiichi Sankyo, Nippon Eli-Lilly, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim. The remaining authors (HT, YM, and MN) declare that they have no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.